/AMPE
AMPE Stock - Ampio Pharmaceuticals, Inc.
Healthcare|BiotechnologyOTC
$0.01+0.00%
+$0.00 (+0.00%) • Dec 19
39
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AMPE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.00
RISK/REWARD1:0.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta5.57
52W High$0.16
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-250,000 | $-2,079,000 | $-1,094,000 | $-1,178,000 | $-1,272,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,518,000 | $-20,382,000 | $-20,571,000 | $-15,834,000 | $-18,576,000 |
| Net Income | $-8,632,000 | $-16,337,000 | $-17,075,000 | $-15,894,000 | $-13,630,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-10.67 | $-11.24 | $-18.79 | $-28.63 | $-18.32 |
Company Overview
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AMPEBeat Rate
36%
Last 14 quarters
Avg Surprise
-3557.3%
EPS vs Estimate
Beats / Misses
5/3
6 met exactly
Latest EPS
$-2.48
Q1 2024
EPS Surprise History
Q2 22
-50.0%
$-9.00vs$-6.00
Q3 22
0.0%
$-6.00vs$-6.00
Q4 22
-49900.0%
$-10.00vs$-0.02
Q1 23
+40.0%
$-3.60vs$-6.00
Q2 23
+13.3%
$-5.20vs$-6.00
Q3 23
+70.0%
$-1.80vs$-6.00
Q4 23
+74.5%
$-1.53vs$-6.00
Q1 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 28, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 13, 2024 | — | — | — | — |
Q3 2024 | Sep 30, 2024 | — | — | — | — |
Q2 2024 | May 24, 2024 | — | — | — | — |
Q1 2024 | Mar 27, 2024 | — | $-2.48 | — | — |
Q4 2023 | Nov 14, 2023 | $-6.00 | $-1.53 | +74.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-6.00 | $-1.80 | +70.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-6.00 | $-5.20 | +13.3% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-6.00 | $-3.60 | +40.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.02 | $-10.00 | -49900.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-6.00 | $-6.00 | 0.0% | = MET |
Q2 2022 | May 16, 2022 | $-6.00 | $-9.00 | -50.0% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-6.00 | $-11.99 | -99.8% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-6.00 | $-6.00 | 0.0% | = MET |
Q3 2021 | Aug 4, 2021 | $-6.00 | $-6.00 | 0.0% | = MET |
Q2 2021 | May 5, 2021 | $-6.00 | $-6.00 | 0.0% | = MET |
Q1 2021 | Mar 3, 2021 | $-6.00 | $-6.00 | 0.0% | = MET |
Q4 2020 | Nov 3, 2020 | $-6.00 | $-6.00 | 0.0% | = MET |
Q3 2020 | Jul 31, 2020 | $-11.99 | $-6.00 | +50.0% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about AMPE
What is AMPE's current stock price?
Ampio Pharmaceuticals, Inc. (AMPE) is currently trading at $0.01 per share. The stock has moved +0.00% today.
What is the analyst price target for AMPE?
No analyst price targets are currently available for this stock.
What sector is Ampio Pharmaceuticals, Inc. in?
Ampio Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is AMPE's market cap?
Ampio Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does AMPE pay dividends?
No, Ampio Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARNI
Arno Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
BTTX
Better Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
BXRXQ
Baudax Bio, Inc.
$0.00
Mkt Cap: $0.0B
CALA
Calithera Biosciences, Inc.
$0.00
Mkt Cap: $0.0B
IVBT
Innovation1 Biotech Inc.
$0.00
Mkt Cap: $0.0B
KLDO
Kaleido Biosciences, Inc.
$0.00
Mkt Cap: $0.0B
ONPH
Oncology Pharma Inc.
$0.01
Mkt Cap: $0.0B
PANC
Panacos Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
STAB
Statera Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
TNGNQ
Tengion, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to AMPE for comparison